Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

  • Kristy J. Gotink
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Henk J. Broxterman
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Mariette Labots
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Richard R. de Haas
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Henk Dekker
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Richard J. Honeywell
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Michelle A. Rudek
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Laurens V. Beerepoot
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • René J. Musters
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Gerrit Jansen
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Arjan W. Griffioen
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Yehuda G. Assaraf
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Roberto Pili
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Godefridus J. Peters
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York
  • Henk M.W. Verheul
    Authors' Affiliations: Departments of 1Medical Oncology, 2Physiology, and 3Rheumatology, VU University Medical Center, Amsterdam; 4Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, the Netherlands; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; 6The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and 7Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York

Description

<jats:title>Abstract</jats:title> <jats:p>Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an important clinical problem, but its underlying mechanisms are largely unknown. We analyzed tumor sunitinib levels in mice and patients and studied sensitivity and resistance mechanisms to sunitinib.</jats:p> <jats:p>Experimental Design: Intratumoral and plasma sunitinib concentrations in mice and patients were determined. Sunitinib exposure on tumor cell proliferation was examined. Resistant tumor cells were derived by continuous exposure and studied for alterations in intracellular sunitinib accumulation and activity.</jats:p> <jats:p>Results: Intratumoral concentrations of sunitinib in mice and patients were 10.9 ± 0.5 and 9.5 ± 2.4 μmol/L, respectively, whereas plasma concentrations were 10-fold lower, 1.0 ± 0.1 and 0.3 ± 0.1 μmol/L, respectively. Sunitinib inhibited tumor cell growth at clinically relevant concentrations in vitro, with IC50 values of 1.4 to 2.3 μmol/L. Continuous exposure to sunitinib resulted in resistance of 786-O renal and HT-29 colon cancer cells. Fluorescent microscopy revealed intracellular sunitinib distribution to acidic lysosomes, which were significantly higher expressed in resistant cells. A 1.7- to 2.5-fold higher sunitinib concentration in resistant cells was measured because of increased lysosomal sequestration. Despite the higher intracellular sunitinib accumulation, levels of the key signaling p-Akt and p-ERK 1/2 were unaffected and comparable with untreated parental cells, indicating reduced effectiveness of sunitinib.</jats:p> <jats:p>Conclusion: We report that sunitinib inhibits tumor cell proliferation at clinically relevant concentrations and found lysosomal sequestration to be a novel mechanism of sunitinib resistance. This finding warrants clinical evaluation whether targeting lysosomal function will overcome sunitinib resistance. Clin Cancer Res; 17(23); 7337–46. ©2011 AACR.</jats:p>

Journal

  • Clinical Cancer Research

    Clinical Cancer Research 17 (23), 7337-7346, 2011-11-30

    American Association for Cancer Research (AACR)

Citations (7)*help

See more

Details 詳細情報について

Report a problem

Back to top